Breaking News Instant updates and real-time market news.

CALA

Calithera Biosciences

$3.09

-0.18 (-5.50%)

, SGEN

Seattle Genetics

$85.32

9.31 (12.25%)

04:55
10/01/19
10/01
04:55
10/01/19
04:55

European Society for Medical Oncology to hold a conference

ESMO Congress 2019 will be held in Barcelona, Spain on September 27-October 1.

CALA

Calithera Biosciences

$3.09

-0.18 (-5.50%)

SGEN

Seattle Genetics

$85.32

9.31 (12.25%)

GTHX

G1 Therapeutics

$22.81

-11.12 (-32.77%)

AZN

AstraZeneca

$44.54

-0.75 (-1.66%)

GSK

GlaxoSmithKline

$42.69

0.35 (0.83%)

AMGN

Amgen

$193.51

-1.41 (-0.72%)

ABBV

AbbVie

$75.72

0.87 (1.16%)

IMGN

ImmunoGen

$2.42

-0.3 (-11.03%)

MRK

Merck

$84.19

1.27 (1.53%)

DCPH

Deciphera

$33.96

1.45 (4.46%)

TROV

Trovagene

$1.50

0.035 (2.40%)

VAR

Varian Medical

$119.06

1 (0.85%)

TAK

Takeda Pharmaceutical

$17.20

-0.15 (-0.86%)

NEO

NeoGenomics

$19.10

-0.02 (-0.10%)

LLY

Eli Lilly

$111.82

-0.53 (-0.47%)

PFE

Pfizer

$35.92

-0.3 (-0.83%)

SNY

Sanofi

$46.35

0.1 (0.22%)

NVS

Novartis

$86.95

-0.41 (-0.47%)

BAX

Baxter

$87.41

1.48 (1.72%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$50.71

0.5 (1.00%)

EXEL

Exelixis

$17.68

-0.32 (-1.78%)

FGEN

FibroGen

$36.95

-0.79 (-2.09%)

FMS

Fresenius Medical

$33.65

-0.02 (-0.06%)

GH

Guardant Health

$63.82

1.25 (2.00%)

IBM

IBM

$145.49

2.2 (1.54%)

HALO

Halozyme

$15.51

0.32 (2.11%)

NSTG

NanoString

$21.57

0.35 (1.65%)

  • 01

    Oct

  • 01

    Oct

  • 01

    Oct

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 03

    Oct

  • 03

    Oct

  • 03

    Oct

  • 04

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 31

    Oct

  • 13

    Nov

  • 14

    Mar

CALA Calithera Biosciences
$3.09

-0.18 (-5.50%)

05/30/19
SBSH
05/30/19
INITIATION
Target $10
SBSH
Buy
Calithera Biosciences assumed with a Buy at Citi
Citi analyst Mohit Bansal assumed coverage Calithera Biosciences with a Buy rating and $10 price target. Under a prior analyst, Citi had a Buy rating on the shares with a $7 price target. Positive data mid-year from the small metastatic renal cell carcinoma trial could have read-through to the Cabo trial, Bansal tells investors in a research note.
SGEN Seattle Genetics
$85.32

9.31 (12.25%)

09/27/19
09/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Western Union (WU) upgraded to Buy from Neutral at Guggenheim with analyst Jeff Cantwell citing what he called the company's "positive" investor day where management outlined "a solid 3-year growth trajectory." 2. Applied Genetic (AGTC) upgraded to Outperform from Market Perform at BMO Capital with analyst Matthew Luchini saying the early XLRP data suggest potential for vision stabilization in peripherally treated patients and vision improvement in centrally treated patients. 3. Seattle Genetics (SGEN) upgraded to Buy from Neutral at Goldman Sachs with analyst Salveen Richter saying with continued Adcetris growth in Hodgkin's lymphoma and peripheral T cell lymphoma, he expects "multiple near-term pipeline drivers to cement" the company's transition into a multi-product oncology company. 4. Match Group (MTCH) upgraded to Outperform from In Line at Evercore ISI. 5. Texas Instruments (TXN) upgraded to Buy from Neutral at BofA/Merrill with analyst Vivek Arya saying he is positive on Texas Instruments' market share gains, stronger free cash flow returns, stronger positioning in growth areas such as 5G, Internet-of-Things, and Electric vehicles. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/19
PIPR
09/29/19
NO CHANGE
Target $20
PIPR
Overweight
Piper Jaffray says some may be disappointed by Immunomedics TROPHY response rate
Piper Jaffray analyst Joseph Catanzaro notes that Immunomedics (IMMU) presented interim data from the Phase II TROPHY study of sacituzumab govitecan in postchemo/CPI urothelial bladder cancer at ESMO. Overall, the response rate of 29% is consistent with prior Phase I data, but he does believe some could be disappointed by this number as it relates to Seattle Genetics' (SGEN) 44% ORR for EV. Catanzaro would await more mature data before drawing any definitive conclusions on the competitive positioning of sacituzumab and EV in post-chemo/IO UBC, but ultimately believes the SC ORR in a larger cohort is approvable and that both drugs will play important roles in this landscape. He reirerates an Overweight rating and $20 price target on Immunomedics's shares.
09/29/19
PIPR
09/29/19
NO CHANGE
Target $95
PIPR
Overweight
Seattle Genetics price target raised to $95 from $75 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro raised his price target for Seattle Genetics to $95 from $75 after the company presented a "compelling" initial response rate of 71% for the combination of EV and pembrolizumab in 1st-line cisplatin-ineligible urothelial bladder cancer. While "admittedly early," these data compare very favorably to current standard of care and emerging IO combos, he contends. As such, the analyst believes it is reasonable to layer in this opportunity into his EV model, which he previously excluded. Catanzaro reiterates an Overweight rating on the shares and sees potential for further upside from additional UBC opportunities and possibly tucatinib in HER2+ mCRC.
09/30/19
STFL
09/30/19
NO CHANGE
Target $74
STFL
Hold
Seattle Genetics' EV-103 data 'stole the spotlight' at ESMO, says Stifel
Stifel analyst Stephen Willey, in a note to investors partially titled "EV-103 Data Steals the ESMO Spotlight," said he is incrementally more-positive on Seattle Genetics shares after the first presentation of Phase 1 EV-103 data, calling it "one of the more-impressive data sets observed at this ESMO meeting." Management seems ready and eager to leverage this preliminary data into an Phase 3 registrational trial intended to establish EV as a first-line standard-of-care therapy, said Willey, who believes EV is an important part of the longer-term diversification thesis for Seattle Genetics. He keeps a Hold rating on the stock, but raised his price target for Seattle Genetics shares to $74 from $69.
GTHX G1 Therapeutics
$22.81

-11.12 (-32.77%)

02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
G1 Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty started G1 Therapeutics with a Buy rating and $55 price target.
02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
B. Riley FBR starts G1 Therapeutics with Buy rating, $55 price target
B. Riley FBR analyst Harshita Polishetty initiated coverage of G1 Therapeutics with a Buy rating and $55 price target. G1's lead candidate, trilaciclib, has the potential to address myelotoxicity and improve overall survival in chemotherapy-associated treatment regimens, Polishetty tells investors in a research note. Further, Lerociclib, although fourth to market, demonstrates potential to be best in class given its clean safety profile thus far adds the analyst. She also believes G1T48 allows for competitive pricing when both lerociclib and G1T48 hit the market.
06/18/19
HCWC
06/18/19
NO CHANGE
HCWC
G1 Therapeutics trial results 'important,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $71 price target on G1 Therapeutics. The analyst noted that G1 Therapeutics' topline OS improvements from its randomized, open-label Phase 2 trial evaluating trilaciclib in metastatic triple-negative breast cancer were "statistically significant in both treatment arms compared with the control arm." White believes that "an OS benefit seen in a small three-arm trial like this is an important result" and added that "the company can now pursue an efficacy benefit as well as the myelopreservation pathway... for commercialization."
08/08/19
JPMS
08/08/19
UPGRADE
Target $45
JPMS
Overweight
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded G1 Therapeutics to Overweight from Neutral and raised his price target for the shares to $45 from $38. The analyst sees a "string of important key catalysts" in the second half of 2019 and first half of 2020 for G1's pipeline. Rama now includes G1T48 in his model with initial phase 1 data in ER+/HER2- breast cancer coming at the end of September. Further, at current share levels, the analyst believes limited value is being ascribed to lerociclib.
AZN AstraZeneca
$44.54

-0.75 (-1.66%)

08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
09/03/19
DZBN
09/03/19
DOWNGRADE
DZBN
Sell
AstraZeneca downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Elmar Kraus downgraded AstraZeneca to Sell from Hold with a price target of 66 pounds.
09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Competitor PARP data an incremental negative for Clovis, says JPMorgan
JPMorgan analyst Cory Kasimov said he views the Phase 3 data presented by AstraZeneca (AZN) and Merck (MRK) on their PARP inhibitor Lynparza in previously treated prostate cancer as incrementally negative to Clovis (CLVS), which has "a lot riding on the prostate indication" since its Rubraca is "neck-and-neck with the competition to be first to market." While there wasn't anything bad reported at the ESMO meeting from Clovis' own prostate update, AstraZeneca "looks primed to come to market with a much more robust data set" and Clovis may "be playing catch-up" in another cancer indication, said Kasimov, who keeps a Neutral rating on Clovis shares.
GSK GlaxoSmithKline
$42.69

0.35 (0.83%)

08/13/19
JPMS
08/13/19
INITIATION
JPMS
Neutral
GlaxoSmithKline reinstated with a Neutral at JPMorgan
JPMorgan analyst James Gordon reinstated coverage of GlaxoSmithKline with a Neutral rating and 1,700p price target. The analyst sees the stock near-term being Brexit and currency moves.
09/03/19
SOCG
09/03/19
UPGRADE
SOCG
Buy
GlaxoSmithKline upgraded to Buy from Sell at Societe Generale
09/03/19
SOCG
09/03/19
UPGRADE
SOCG
Buy
Societe Generale double upgrades GlaxoSmithKline to Buy
As previously reported, Societe Generale analyst Justin Smith upgraded GlaxoSmithKline to Buy from Sell in a research note titled 'An intriguing metamorphosis.' The analyst said he waited to upgrade the stock, despite liking "all the management and capital allocation changes" that new CEO Emma Walmsley has made in her first two years in charge, because he wanted to see "clear evidence of improving innovation" with GlaxoSmithKline's Pharma business. Smith now sees five high profile assets in Phase 3 that will release results in the next 3-4 years, giving improved pipeline visibility, and leaving the analyst forecasting "above-average sales growth from 2023."
09/04/19
COWN
09/04/19
NO CHANGE
Target $48
COWN
Outperform
Pfizer shares remain attractively valued, says Cowen
Cowen analyst Steve Scalia updated his Pfizer (PFE) model following Q2 results, the closing of the Glaxo (GSK) Consumer joint venture, and the announcement that its Upjohn business would be divested and combined with Mylan (MYL). The analyst lowered his estimates to reflect what is left at the company and despite his revision feels the shares remain attractively valued. Scalia reiterated his Outperform rating and $48 price target on Pfizer shares.
AMGN Amgen
$193.51

-1.41 (-0.72%)

09/27/19
FBCO
09/27/19
NO CHANGE
Target $115
FBCO
Outperform
Mirati Therapeutics price target lowered to $115 from $120 at Credit Suisse
Credit Suisse analyst Evan Seigerman maintained an Outperform rating on Mirati Therapeutics (MRTX) and lowered his price target to $115 from $120 following the interim data update from the company's only clinical stage KRAS inhibitor competitor from Amgen (AMGN), AMG 510. In a research note to investors, Seigerman says he believes Amgen's AMG 510 is more than six months ahead of MRTX849 and sees potential for the first-mover to capture significant share given the high unmet need. The analyst remains positive on both programs, but is taking a conservative view as he awaits interim MRTX849 data.
09/29/19
PIPR
09/29/19
NO CHANGE
Target $218
PIPR
Overweight
Piper Jaffray remains bullish on Amgen after update on AMG 510
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and a $218 price target on Amgen's shares after an update on AMG 510 at ESMO. As expected, no additional durability data were provided for mutant KRAS-G12C NSCLC patients, but initial responses and follow up from a more meaningful number of CRC patients were presented at the RP2D. While durability remains immature, the company believes the lack of improved responses in CRC supports further development of AMG 510 as a combo treatment in this patient population, he contends.
09/30/19
FBCO
09/30/19
NO CHANGE
Target $225
FBCO
Outperform
Credit Suisse still bullish on Amgen, sees possible weakness following ESMO data
Commenting on Amgen's updated data for AMG510 in colorectal and appendiceal cancers presented at ESMO, Credit Suisse analyst Evan Seigerman notes that the objective response rate was much lower than what he saw in non-small cell lung cancer at 3% in all patients and 8% in the highdose cohort. While there was a decent disease control rate, the analyst argues that it is clear that biologic differences between lung and CRC patients are driving significantly different clinical results. Given the divergence between the lung cohort and the CRC patients, Seigerman expects potential weakness in Amgen's shares. Nonetheless, the analyst remains positive on AMG 510 in NSCLC with potential for other combinations or monotherapy, and reiterates an Outperform rating and $225 price target on the stock.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Amgen colorectal cancer update 'underwhelming,' says JPMorgan
Amgen's updated AMG 510 KRAS data presented over the weekend did little to boost expectations for monotherapy treatment in colorectal cancer, JPMorgan analyst Cory Kasimov tells investors in a research note. Most of the early enthusiasm for the KRAS class is for lung cancer, and this is likely to remain the case for the time being, adds the analyst. He views Amgen's weekend update as "underwhelming" and keeps a Neutral rating on the shares. Kasimov thinks the colorectal cancer indication will ultimately require a combo approach.
ABBV AbbVie
$75.72

0.87 (1.16%)

09/25/19
PIPR
09/25/19
NO CHANGE
Target $81
PIPR
Overweight
AbbVie survey supports above-consensus estimates, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on AbbVie (ABBV) shares with an $81 price target following a new rheumatologist survey by his firm's partners Spherix Global Insights. The survey indicates "robust" expectations for the company's oral JAK1 inhibitor Rinvoq, Raymond tells investors in a research note. Rheumatologists project that in six months, Rinvoq will leapfrog Eli Lilly's (LLY) Olumiant to become the second-most prescribed JAK with 5% share, says the analyst, citing the survey. He believes this supports his above-consensus Rinvoq revenue estimates.
09/26/19
SBSH
09/26/19
UPGRADE
SBSH
Buy
AbbVie upgraded to Buy from Neutral at Citi
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral.
09/26/19
SBSH
09/26/19
UPGRADE
Target $90
SBSH
Buy
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential of both Skyrizi and Rinvoq.
09/26/19
09/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Outperform from Market Perform at Wells Fargo analyst Timothy Willi saying the company's fundamentals remain strong while investor sentiment is "overly negative and close to inflecting." 2. Whirlpool (WHR) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Rehaut saying he expects U.S. industry shipments to be more stable year-over-year through the end of 2019 and show "modest" growth in 2020. 3. Boston Beer (SAM) upgraded to Outperform from Market Perform at BMO Capital with analyst Amit Sharma saying Truly is "primed to capture" strong consumer demand and higher distribution/shelf space for hard seltzer. 4. AbbVie (ABBV) upgraded to Buy from Neutral at Citi with analyst Andrew Baum saying he believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." 5. Hologic (HOLX) upgraded to Buy from Neutral at BofA/Merrill with analyst Ivy Ma saying she sees the company being on "steadier footing with organic growth upside in FY20" thanks to its tuck-in acquisitions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IMGN ImmunoGen
$2.42

-0.3 (-11.03%)

05/06/19
05/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Sinclair Broadcast (SBGI) upgraded to Buy from Neutral at B. Riley FBR with analyst Barton Crockett saying yhe company's deal to acquire 21 regional sports networks from Disney (DIS) at valuation of $10.6B "looks like a home-run". 2. ImmunoGen (IMGN) upgraded to Buy from Neutral at H.C. Wainwright with analyst Debjit Chattopadhyay seeing 40% downside risk to the stock if the FDA does not consider mirvetuximab to be a clinically meaningful addition to the armametum against ovarian cancer versus a 145% upside potential. 3. Dish (DISH) upgraded to Neutral from Underperform at Credit Suisse with analyst Douglas Mitchelson saying he finds that risk/reward and potential catalysts across wireless and Pay TV are now in balance. 4. Post Holdings (POST) upgraded to Buy from Neutral at Goldman Sachs with analyst Jason English stating he views the recent pullback as a buying opportunity as he thinks transient headwinds were the reason results missed investor expectations in Q2. 5. Dentsply Sirona (XRAY) upgraded to Outperform from Market Perform at Barrington with analyst Michael Petusky saying the company's turnaround is "now on a firm, provable footing". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/15/19
GUGG
05/15/19
DOWNGRADE
GUGG
Neutral
ImmunoGen downgraded to Neutral from Buy at Guggenheim
05/15/19
HCWC
05/15/19
NO CHANGE
Target $4
HCWC
Buy
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
H.C. Wainwright analyst Debjit Chattopadhyay said he had "misplaced optimism" about the path forward for ImmunoGen's mirvetuximab and admits to having been "wrong again" about the stock after the company disclosed that the FDA has recommended a new Phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine in patients with high folate receptor alpha-positive, platinum-resistant ovarian cancer. The analyst believes the subsequent study, likely to be initiated during Q4, will likely mimic the FORWARD I Phase 3 program, but focus primarily on high FRalpha expressing patients. He "conservatively" assumes about 36 months from trial start to finish and now thinks potential commercialization won't come until the beginning of 2023. Chattopadhyay lowered his price target on ImmunoGen shares to $4 from $7 but keeps a Buy rating on the stock, which is down 31% to $2.19 in early trading.
09/29/19
PIPR
09/29/19
NO CHANGE
Target $2.5
PIPR
Neutral
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro notes that ImmunoGen presented full data from the failed FORWARD I study for lead asset mirvetuximab in FRalpha-expressing r/r ovarian cancer. The analyst believes that focus following the presentation will like fall on the revelation that a change in methodology to assess biomarker positivity may have contributed to enrollment of patients that did not meet the intended threshold for FRalpha positivity. A retrospective analysis showed that if the original screening method had been used, the trial could have been positive per its statistical design, with the absolute effect size on PFS benefit in FRalpha-high patients increasing modestly to +2.4 months vs. +1.5 months per protocol, he adds. Catanzaro has a Neutral rating and a $2.50 price target on the shares.
MRK Merck
$84.19

1.27 (1.53%)

08/16/19
08/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Merck (MRK) initiated with an Outperform at SVB Leerink. 2. DocuSign (DOCU) initiated with a Buy at DA Davidson. 3. iQIYI (IQ) initiated with an Underweight at JPMorgan. 4. Goodyear Tire (GT) initiated with an Outperform at Exane BNP Paribas. 5. BlackBerry (BB) initiated with a Neutral at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/19
RHCO
09/18/19
NO CHANGE
Target $14
RHCO
Hold
Lannett price target raised to $14 from $10 at SunTrust
SunTrust analyst Gregg Gilbert raised his price target on Lannett (LCI) to $14, adjusting his model to reflect its potentially significant opportunity with the recent launch of posaconazole - a generic version of Merck's (MRK) Noxafil. The analyst notes that he now models sales and EBITDA at the higher end of the company's FY20 targets while also raising his FY20 EPS view by 19c to $1.33. Gilbert still keeps his Hold rating on the stock, citing the uncertainty around Lannett's capital structure and limited pipeline visibility as well as the challenging environment for generics.
09/30/19
GUGG
09/30/19
INITIATION
Target $12
GUGG
Buy
Guggenheim starts Bellus Health at Buy with $12 price target
As previously reported, Guggenheim analyst Dana Flanders initiated Bellus Health (BLU) with a Buy rating and $12 price target. BLU-5937 for refractory chronic cough is the primary value driver in "a potential multi-billion dollar category," said Flanders, who also sees the opportunity for label expansion and the potential for M&A interest in Bellus. Merck (MRK) acquired Afferent, which also has a P2X3 antagonist asset called gefapixant, in 2016 for $500M upfront and up to $1.25B with milestones, noted Flanders.
DCPH Deciphera
$33.96

1.45 (4.46%)

08/29/19
PIPR
08/29/19
INITIATION
Target $85
PIPR
Neutral
Blueprint Medicines initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Christopher Raymond started Blueprint Medicines (BPMC) with a Neutral rating and $85 price target. The analyst, while impressed with the company's "well demonstrated developmental track record and platform capability," sees a full valuation at current share levels. Further, the competitive disadvantage for Blueprint's lead asset avapritinib relative to Deciphera's (DCPH) ripretinib is not completely understood, Raymond tells investors in a research note.
09/30/19
JEFF
09/30/19
INITIATION
Target $47
JEFF
Buy
Deciphera initiated with a Buy at Jefferies
Jefferies started Deciphera Pharmaceuticals with a Buy rating and $47 price target.
09/30/19
JEFF
09/30/19
INITIATION
Target $47
JEFF
Buy
Jefferies starts Deciphera at Buy, calls one of the most attractive in oncology
Jefferies analyst Eun Yang initiated coverage of Deciphera Pharmaceuticals with a Buy rating and $47 price target. With the recent "strong" Phase data showing clear survival benefits, the company's lead product ripretinib is a "significantly de-risked" asset in digestive tract cancer, Yang tells investors in a research note. With FDA approval likely by the end of 2020, and greater than $1B in revenue potential, Deciphera's current enterprise value of less than $1B offers limited downside risks and upside potential from pipeline products, contends the analyst. She views Deciphera as one of the most attractive opportunities in oncology.
09/30/19
PIPR
09/30/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera data update 'derisking' ahead of 2020 filing, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond continues to recommend Deciphera Pharmaceuticals shares following a more detailed presentation of the Phase 3 Invictus results at the European Society for Medical Oncology meeting. The analyst views today's update as "derisking" heading into an anticipated regulatory filing for ripretinib in Q1 of 2020. The analyst remains a buyer of the stock with an Overweight rating and $55 price target.
TROV Trovagene
$1.50

0.035 (2.40%)

01/07/19
NBLE
01/07/19
INITIATION
Target $5.2
NBLE
Outperform
Trovagene initiated with an Outperform at Noble Financial
Noble Financial analyst Ahu Demir initiated Trovagene with an Outperform rating and $5.20 price target, stating that investors remain skeptical of PLK1 targeting but he foresees upside potential and likes TrovaGene's Onvansertib. He believes further data will be valuable to demonstrate anti-tumor activity and the safety profile of Onvansertib, Demir tells investors.
03/01/19
MAXM
03/01/19
NO CHANGE
Target $8
MAXM
Buy
Trovagene price target lowered to $8 from $18 at Maxim
Maxim analyst Jason McCarthy lowered his post-split price target for Trovagene to $8 from $18, which reflects dilution associated with future capital raises. The analyst keeps a Buy rating on the shares ahead of a "busy" American Association for Cancer Research annual meeting for the company in late March. Trovagene now has three funded clinical trials with Onvansertib, and as updates are provided in 2019, they should, if positive, support a higher valuation, McCarthy tells investors in a research note.
VAR Varian Medical
$119.06

1 (0.85%)

07/17/19
PIPR
07/17/19
NO CHANGE
Target $15
PIPR
Overweight
Competitor recall highlights superiority of ViewRay system, says Piper Jaffray
After a notice appeared yesterday on the FDA website indicating that Elekta had issued a recall on its Unity system, Piper Jaffray analyst Matt O'Brien said he does not want to overstate the impact of this specific recall on ViewRay's (VRAY) ability to win business, but he does think that it highlights the superiority of the MRIdian system compared to Elekta's Unity platform. The analyst, who continues to believe that ViewRay's system is superior not only to Elekta in the MRgRT space but also when compared to "the dominant player," Varian Medical (VAR), keeps an Overweight rating and $15 price target on ViewRay shares.
09/12/19
EVER
09/12/19
UPGRADE
EVER
In Line
Varian Medical upgraded to In Line from Underperform at Evercore ISI
09/12/19
EVER
09/12/19
UPGRADE
Target $123.5
EVER
In Line
Evercore upgrades Varian Medical to In Line on tariff relief from China
Evercore ISI analyst Vijay Kumar upgraded Varian Medical Systems to In Line from Underperform and raised his price target for the shares to $123.50 from $122. The analyst upgraded the shares after Varian received an exemption from China relative to the tariffs on imports from the U.S. The analyst thinks Varian's earnings were hurt by 3%-4% in fiscal 2019 from the tariffs, or 15c-20c per share. However, some of the upside from the tariff relief is offset by lower organic sales assumptions and currency volatility, Kumar tells investors in a research note.
09/23/19
BRRR
09/23/19
NO CHANGE
Target $146
BRRR
Outperform
Varian Medical price target raised to $146 from $142 at Barrington
Barrington analyst Michael Petusky raised his price target for Varian Medical Systems to $146 from $142 after the company held a meeting for investors at this year's ASTRO Conference. Varian remains committed to broadening its "already significant" footprint in the cancer care space and highlighted several ways in which it will deliver value to care providers, patients and payors, Petusky tells investors in a research note. The analyst "strong" believes that the company is well positioned for any potential reimbursement changes that might come as healthcare continues to evolve towards a more value-based model. He keeps an Outperform rating on Varian Medical.
TAK Takeda Pharmaceutical
$17.20

-0.15 (-0.86%)

05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.
08/15/19
DAIW
08/15/19
DOWNGRADE
DAIW
Neutral
Takeda Pharmaceutical downgraded to Neutral from Outperform at Daiwa
Daiwa analyst Kazuaki Hashiguchi downgraded Takeda Pharmaceutical to Neutral from Outperform with a price target of 3,700 yen, down from 4,500 yen.
09/05/19
HCWC
09/05/19
NO CHANGE
HCWC
Buy
H.C. Wainwright says KemPharm may have picked 'best possible' partner in GPC
After KemPharm (KMPH) announced a deal with private equity firm Gurnet Point Capital, H.C. Wainwright analyst Oren Livnat noted that investors reacted negatively to the deal, which he thinks is likely due to the relatively small $10M up-front and the partner being an unknown rather than an obvious ADHD player such as Takeda's (TAK) Shire. However, he thinks the Street is "entirely missing" that GPC "may actually be the best possible partner" given that it previously acquired CNS-focused Corium International and recently put new leadership in place almost entirely made up of recent Shire senior management. Livnat also believes that "deep-pocketed, private" GPC may be more willing than any other player, including Takeda, to provide the needed commercial support to make KP415 a success, he tells investors. He maintains a $3 price target and Buy rating on KemPharm shares.
09/24/19
JEFF
09/24/19
INITIATION
JEFF
Buy
Takeda Pharmaceutical initiated with a Buy at Jefferies
Jefferies analyst Stephen Barker started Takeda Pharmaceutical with a Buy rating and 6,000 yen price target.
NEO NeoGenomics
$19.10

-0.02 (-0.10%)

01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
03/12/19
FANA
03/12/19
NO CHANGE
Target $23
FANA
Strong Buy
NeoGenomics target raised to $23 after company visit at First Analysis
First Analysis analyst Joseph Munda raised his price target for NeoGenomics to $23 from $22 and reiterates a Strong Buy rating on the shares after visiting the company's headquarters. The analyst says a "deep dive" with management on the integration of Genoptix and the pharma services business "raised his conviction level" for the shares. NeoGenomics offers a "one-stop oncology testing shop" that is well positioned to scale its pharma services business and continue to take clinical testing market share, Munda tells investors in a research note.
03/29/19
NEED
03/29/19
NO CHANGE
Target $22
NEED
Buy
NeoGenomics price target raised to $22 from $19 at Needham
Needham analyst Stephen Unger raised his price target on NeoGenomics to $22 and kept his Buy rating after meeting with its CEO Doug VanOort. The analyst says the discussions left him "incrementally bullish" about the company's prospects driven by the doubling of its sales force to 70 representatives that could potentially increase its test volumes. Unger adds that the company's integration of Genoptix is proceeding as planned with no negative surprises, and the "development of a testing panel using next-generation sequencing remains on track for FDA submission before the end of 2019."
04/23/19
BNCH
04/23/19
NO CHANGE
BNCH
UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark
Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.
LLY Eli Lilly
$111.82

-0.53 (-0.47%)

07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/09/19
PIPR
09/09/19
NO CHANGE
Target $85
PIPR
Neutral
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he thinks Eli Lilly (LLY) issued an "impressive update" on selpercatinib at the World Lung meeting, raising the bar for Blueprint Medicines' (BPMC) pralsetinib "meaningfully higher." While selpercatinib's "best-in-class" ORR was maintained, initial durability data could be upwards of 50% better than that of pralsetinib, according to Raymond. While cautioning that his comparison is highly preliminary, Raymond said he worries that LOXO-292's superiority gap against pralsetinib "may be widening." He keeps a Neutral rating on Blueprint shares, which are down about 3% in morning trading to $75.89.
PFE Pfizer
$35.92

-0.3 (-0.83%)

08/28/19
08/28/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Papa John's (PZZA) upgraded to Buy from Hold at Stifel with analyst Chris O'Cull saying new CEO Rob Lynch's turnaround experience and marketing expertise improves the company's prospects of delivering positive same-restaurant-sales gains over the coming quarters. 2. Targa Resources (TRGP) upgraded to Strong Buy from Outperform at Raymond James with analyst J R Weston saying the recent selloff in the shares is overdone and makes Targa "inexpensive." 3. Livongo Health (LVGO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Ricky Goldwasser saying after the recent selloff, Livongo shares are trading at a discount to peers. 4. Sea Limited (SE) upgraded to Buy from Outperform at CLSA with analyst Marcus Liu saying the 12% pullback in the shares post the company's Q2 results is overdone. 5. Pfizer (PFE) upgraded to Hold from Sell at DZ Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/03/19
HCWC
09/03/19
NO CHANGE
Target $73
HCWC
Buy
uniQure has significant first mover advantage in Hem B, says H.C. Wainwright
After uniQure (QURE) announced it has completed enrollment in the HOPE-B registration study, H.C. Wainwright analyst Debjit Chattopadhyay said he now anticipates a likely commercial launch during the fourth quarter of 2021, which is ahead of his prior expectation for launch in the second half of 2022. He sees AMT-061 with a 12+ month lead to be the first commercially viable gene therapy for Hemophilia B and contends the "first mover advantage is likely to be significant," especially if the product's safety profile, established manufacturing, clinical outcomes and clinical lead are compelling enough for Pfizer (PFE) to have second thoughts for its "potentially inferior me-too program" for SPK-9001. Chattopadhyay keeps a Buy rating and $73 price target on uniQure shares.
09/19/19
JPMS
09/19/19
NO CHANGE
Target $37
JPMS
Neutral
Pfizer price target lowered to $37 from $46 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for Pfizer (PFE) to $37 from $46 and keeps a Neutral rating on the shares. While the Mylan (MYL)/Upjohn transaction creates a smaller, innovation-driven biopharma business and increases the company's near-term growth prospects, Pfizer's multiple is ahead of itself with the remaining company trading near the top end of the major pharma valuation range, Schott tells investors in a research note. He points out that Pfizer is facing "another major patent cycle" post 2025.
SNY Sanofi
$46.35

0.1 (0.22%)

09/20/19
MSCO
09/20/19
UPGRADE
MSCO
Overweight
Morgan Stanley upgrades 'defensive' Sanofi to Overweight
As previously reported, Morgan Stanley upgraded Sanofi to Overweight from Equal Weight with analyst Mark Purcell arguing that the company has the lowest risk growth outlook in European pharma given its lack of major patent cliffs and the "largely de-risked" nature of pipeline drugs in the late stages. He thinks Sanofi's defensive qualities position it as a key holding in the current environment and also believes the company's new CEO Paul Hudson has significant optionality to unlock shareholder value, Purcell tells investors. He raised his price target on Sanofi shares to EUR90 from EUR79.
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy from Neutral at Guggenheim
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.
NVS Novartis
$86.95

-0.41 (-0.47%)

08/12/19
LEHM
08/12/19
NO CHANGE
Target $31
LEHM
Overweight
Coherus should be bought on weakness from Enbrel ruling, says Barclays
Barclays analyst Balaji Prasad recommends buying shares of Coherus Biosciences (CHRS) on any weakness from Amgen's (AMGN) favorable Enbrel patent ruling against Novartis (NVS). Coherus is developing its own Enbrel generic, says the analyst, whose model already factors a launch in Q2 of 2029, following the expiration of the last U.S. Enbrel patent. As such, Prasad is making no change to his estimates following Friday's decision. He remains positive on Coherus and would use any share weakness as an opportunity to add a "fundamentally sound company." Prasad reiterates an Overweight rating on the shares with a $31 price target.
08/13/19
OPCO
08/13/19
NO CHANGE
Target $230
OPCO
Outperform
Amgen price target raised to $230 from $210 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.
BAX Baxter
$87.41

1.48 (1.72%)

07/26/19
BMOC
07/26/19
NO CHANGE
Target $95
BMOC
Outperform
Baxter price target raised to $95 from $88 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Baxter to $95 and kept her Outperform rating, saying Q2 has changed the trajectory of mixed quarters with a 4% operational growth and recovery in its Medication Delivery and Nutrition division. The analyst says the company "room left on the runway" as it expands its product portfolio and gathers operating leverage.
07/26/19
FBCO
07/26/19
NO CHANGE
Target $95
FBCO
Outperform
Baxter price target raised to $95 from $84 at Credit Suisse
Credit Suisse analyst Matt Miksic raised his price target for Baxter to $95 from $84 and maintained an Outperform rating following the company's Q2 results, saying the results help shift the Med Delivery debate towards greater confidence in the 2019 6% growth target. Baxter's performance should help to reduce uncertainty on this issue and create more interest among investors, according to the analyst.
07/26/19
RAJA
07/26/19
NO CHANGE
Target $95
RAJA
Outperform
Baxter price target raised to $95 from $84 at Raymond James
Raymond James analyst Lawrence Keusch raised his price target on Baxter shares to $95 from $84 following a "solid" quarter marked by outperformance in its Advanced Surgery, Pharmaceuticals, and Medication Delivery segments. In particular, the recent momentum in Medication Delivery gives him increasing confidence in Baxter's ability to accelerate growth in the second half, said Keusch, who keeps an Outperform rating on the stock.
09/10/19
PIPR
09/10/19
NO CHANGE
PIPR
Overweight
Baxter makes 'solid tuck-in' deal buying Cheetah Medical, says Piper Jaffray
After Baxter announced a deal to buy hemodynamic monitoring solutions maker Cheetah Medical for up to $230M in total consideration, Piper Jaffray analyst Matt O'Brien called the acquisition a "solid tuck-in" that presents significant cross-selling opportunities. Baxter continues to execute at a high level, according to O'Brien, who reiterated his Overweight rating on the stock.
BAYRY Bayer
$0.00

(0.00%)

06/04/19
PIPR
06/04/19
NO CHANGE
Target $32
PIPR
Overweight
Piper remains buyer of Arvinas after 'transformative' Bayer alliance
Piper Jaffray analyst Edward Tenthoff views Arvinas' (ARVN) alliance with Bayer (BAYRY) as "transformative." He's a buyer of the stock ahead of the Phase I ARV-110 data in metastatic castrate resistance prostate cancer in the second half of 2019. The analyst estimates Arvinas now holds pro forma cash of $225M to fund operations into the second half of 2021. Tenthoff reiterates an Overweight rating on Bayer with a $32 price target.
07/10/19
WBLR
07/10/19
NO CHANGE
WBLR
Market Perform
Elanco combination with Bayer unlikely for many reasons, says William Blair
Shares of Elanco Animal Health (ELAN) have been unusually volatility over the past two days, William Blair analyst John Kreger tells investors in a research note. On Monday, the FDA approved a generic version of the company's largest product, Rumensin, and yesterday, the media reported speculation that Bayer (BAYRY) has approached Elanco about combining their animal health businesses, the analyst explains. He believes that while a negative development, the Rumensin generic had been expected and thus does not change his modeling assumptions. The Bayer speculation is more surprising but does not seem likely to happen "for a number of reasons," says Kreger. Elanco's largest challenge is bolstering its organic revenue growth, and buying a large company that is growing at a slower pace would only add to this challenge, according the analyst. Further, Elanco has committed to deleverage its balance sheet in the coming year, he adds. And lastly, Kreger believes there could be antitrust challenges from such a large combination. He keeps a Market Perform rating on Elanco shares.
08/15/19
UBSW
08/15/19
UPGRADE
Target $30
UBSW
Neutral
Elanco upgraded to Neutral from Sell at UBS
UBS analyst Navin Jacob upgraded Elanco Animal Health (ELAN) to Neutral from Sell with a price target of $30, down from $31. While the analyst still see risks to the company's fundamentals from African swine fever and generic Rumensin, he believes the shares are more fairly valued at current levels. Further, some of these headwinds may be offset by companion animal strength, Jacob tells investors in a research note. While concerns of a potential deal with Bayer (BAYRY) have pushed Elanco shares lower, "forecastable" concerns are built in at current levels, says the analyst.
08/26/19
BOFA
08/26/19
DOWNGRADE
Target $30
BOFA
Neutral
BofA/Merrill downgrades Elanco to Neutral on Bayer deal uncertainty
BofA/Merrill analyst Michael Ryskin downgraded Elanco Animal Health (ELAN) to Neutral from Buy with a $30 price target. While the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues, Ryskin tells investors in a research note. The analyst does not expect answers until nearer to deal close, which is expected in mid-2020.
BMY Bristol-Myers
$50.71

0.5 (1.00%)

08/14/19
ATLE
08/14/19
UPGRADE
Target $63
ATLE
Overweight
Bristol-Myers upgraded to Overweight from Neutral at Atlantic Equities
Atlantic Equities analyst Steve Chesney upgraded Bristol-Myers Squibb to Overweight from Neutral and raised his price target for the shares to $63 from $51.
08/14/19
08/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Evercore Partners (EVR) upgraded to Neutral from Sell at Goldman Sachs with analyst Richard Ramsden saying believes that stronger U.S. large cap deal activity than he previously expected should support Evercore's revenues. 2. Sanofi (SNY) upgraded to Buy from Neutral at UBS with analyst Laura Sutcliffe saying she sees signs of a turnaround for the company and believes its pipeline can fixed ahead of patent expiration. 3. Bristol-Myers (BMY) upgraded to Overweight from Neutral at Atlantic Equities. 4. Horizon Pharma (HZNP) upgraded to Outperform from Market Perform at BMO Capital with analyst Gary Nachman citing the company's "strong" Q2 results driven by Krystexxa. 5. Ferrari (RACE) upgraded to Buy from Neutral at Goldman Sachs with analyst George Galliers citing the company's Q2 results earlier this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/19
MZHO
08/19/19
DOWNGRADE
MZHO
Neutral
Amgen, Celgene downgraded to Neutral on valuation at Mizuho
As previously reported, Mizuho analyst Salim Syed downgraded Amgen (AMGN) and Celgene (CELG), each to Neutral from Buy, "solely" on the stock's current trading prices nearing what the analyst views as appropriate valuations. Amgen has run up over the last week by about 10% following a "very clean Enbrel litigation win," but the stock price now gives full credit for its Enbrel IP, said Syed, who raised his price target on Amgen shares to $212 from $208. He also cut his price target on Celgene shares to $100 from $103, based on a calculation of one Bristol-Myers (BMY) share being worth $47, plus $50 cash per share and $3 for a risk-adjusted CVR valuation.
08/27/19
RBCM
08/27/19
NO CHANGE
Target $206
RBCM
Sector Perform
Amgen price target raised to $206 from $192 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Amgen to $206, saying that despite the "sticker shock" of its $13.4B deal for the Otezla franchise, the transaction is expected to be immediately accretive to earnings and fitting well with its existing inflammation and immunology portfolio. The analyst believes that Amgen should be able to grow revenue "majorly" over the next 3 years as it leverages Otezla potential with its legal victory on Enbrel, stating that there is a case for its multiple to re-rate higher. MacKay keeps his Sector Perform rating on Amgen shares as he awaits for its emerging pipeline to also "fill the shoes" of its maturing assets.
EXEL Exelixis
$17.68

-0.32 (-1.78%)

06/17/19
STFL
06/17/19
NO CHANGE
STFL
Stifel would be surprised if another suitor tries to outbid Pfizer for Array
After Pfizer (PFE) announced an agreement to acquire Array BioPharma (ARRY) for $48 per share in cash, Stifel analyst Stephen Willey said he views the deal as a "fitting," "logical" and "appropriate" conclusion for Array shareholders and he would be "very surprised" if another suitor tried to compete with a higher priced offer. He believes a "very fair valuation" is implied by the $11.4B price Pfizer has agreed to pay, Willey added. He also sees the deal announcement providing a tailwind for the sector, specifically for small-to-mid cap oncology companies that are "perceived to have achieved some meaningful level of de-risking." As examples, he offers Exelixis (EXEL) and Blueprint Medicines (BPMC), though Willey added that a potentially shortened exclusivity runway could make a deal for Exelixis "a bit harder for a strategic to rationalize."
06/18/19
RHCO
06/18/19
DOWNGRADE
Target $48
RHCO
Hold
Array BioPharma downgraded to Hold from Buy at SunTrust
SunTrust analyst Peter Lawson downgraded Array BioPharma (ARRY) to Hold but raised his price target to $48 from $32 after the company announced that it is being acquired by Pfizer (PFE) at that price. The analyst notes that the 79% premium to the company's last closing price looks like a "fair valuation" based on his analysis of past comps and his M&A valuation model. Lawson adds that the the deal is "encouraging" within the biotech space with positive implications for other potential acquisition targets such as Agios Pharmaceuticals (AGIO) and Mirati herapeutics (MRTX) along with companies with strong chemistry such Incyte Corporation (INCY) and Exelixis (EXEL).
06/21/19
WBLR
06/21/19
NO CHANGE
WBLR
Outperform
William Blair an 'aggressive' buyer of Exelixis on weakness from clinical miss
William Blair analyst Andy Hsieh is an "aggressive" buyer of Exelixis (EXEL) shares on weakness after the company's partner Roche (RHHBY) informed the company that the Phase III IMspire170 trial, which assesses the safety and efficacy of the combination of Cotellic and Tecentriq, did not meet the primary endpoint of progression-free survival in treatment-naive melanoma. Hsieh says that while the news is disappointing, he reiterates that his bullish thesis resides in Exelixis's growth potential, driven by the Cabometyx franchise. As a result, the melanoma clinical setback does not impact the analyst's stock outlook. Further, he points out that he and the Street have not modeled revenue contribution from the IMspire170 study. Hsieh keeps an Outperform rating on Exelixis.
07/15/19
PIPR
07/15/19
NO CHANGE
PIPR
Exelixis trial updates 'encouraging,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $45 price target on Exelixis, saying he is "confident" in CABO growth with net product sales forcast of $200M in Q2, $842M for FY19, and $1.08B in FY20. The analyst's note, titled Cabometyx I-O Combo Opportunity Grows in Phase Ib COSMIC-021 Study,' comes after the company announced new protocol updates to Phase Ib COSMIC-021 trial of Cabometyx + Tecentriq, which were spurred by "encouraging early efficacy and safety data in advanced NSCLC and mCRPC cohorts."
FGEN FibroGen
$36.95

-0.79 (-2.09%)

05/29/19
GSCO
05/29/19
INITIATION
Target $45
GSCO
Neutral
FibroGen assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi assumed coverage of FibroGen with a Neutral rating and $45 price target. Prior analyst Terence Flynn had a Neutral rating on the shares with a $56 price target. Following the recent Phase 3 MACE safety results for roxadustat, the analyst sees the shares as range-bound pending further clarity from the FDA.
06/10/19
JEFF
06/10/19
NO CHANGE
Target $75
JEFF
Buy
FibroGen shares may rebound with FDA meeting feedback, says Jefferies
Jefferies analyst Michael Yee says his recent meeting with FibroGen management suggested the company's progress is well on track, with the FDA meeting soon. There could be more disclosure with an FDA agreement soon and a new drug application filing on time in Q3, which "should calm the Street," Yee tells investors in a research note. The analyst thinks the post-FDA meeting disclosure, confirmation of filing, and potentially more detailed data from Phase III could cause shares of FibroGen to rebound.
06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper says buy Akebia before market figures out competitive positoin
After hosting an investor call with Akebia Therapeutics (AKBA) CEO John Butler, Piper Jaffray analyst Christopher Raymond thinks vadadustat's competitive position relative to FibroGen's (FGEN) roxadustat is "stronger, not weaker now." As such, the analyst recommends buying shares of Akebia "before the market begins to figure this out." Raymond left the call incrementally confident in vadadustat "on a number of levels," namely its approvability given Akebia's alignment with FDA on trial design and statistical analysis. He keeps an Overweight rating on the shares with a $22 price target.
07/24/19
HCWC
07/24/19
NO CHANGE
Target $19
HCWC
Buy
Akebia shares at 'excellent entry point,' says H.C. Wainwright
After Akebia (AKBA) announced that its Japanese partner on vadadustat has submitted a New Drug Application in Japan that supports approval for anemia due to chronic kidney disease in both non-dialysis and dialysis patients, H.C. Wainwright analyst Ed Arce noted that this represents the first regulatory submission for vadadustat. The current valuation, with shares trading near 52-week lows, presents "an excellent entry point" given that the primary bear thesis depends on the first-to-market advantage of Fibrogen's (FGEN) roxadustat, which Arce views as "fundamentally flawed," he tells investors. In light of the JNDA submission, as well as the current timeline, Arce pushed back his U.S. and EU market launch and initial sales estimates to early 2022 and trimmed his price target on Akebia shares to $19 from $21, but he keeps a Buy rating on the stock.
FMS Fresenius Medical
$33.65

-0.02 (-0.06%)

10/26/18
UBSW
10/26/18
UPGRADE
UBSW
Buy
Fresenius Medical upgraded to Buy from Neutral at UBS
UBS analyst Ian Douglas-Pennant upgraded Fresenius Medical to Buy while lowering his price target for the shares to EUR 82 from EUR 86. The analyst says the Q3 pre-release selloff presents a buying opportunity.
11/20/18
RHCO
11/20/18
NO CHANGE
Target $46
RHCO
Buy
Fresenius Medical price target lowered to $46 from $62 at SunTrust
SunTrust analyst David MacDonald lowered his price target on Fresenius Medical to $46 to reflect its "soft" Q3 results with a lower implied valuation of 10-times forward EBITDA. The analyst believes that given the mixed fundamentals, the stock is a "show me" story, even though he keeps his Buy rating on Fresenius Medical longer term based on its "solid core volume trends, attractive overarching industry drivers, a diversified business model, and strong free cash generation".
02/21/19
RHCO
02/21/19
NO CHANGE
Target $48
RHCO
Buy
Fresenius Medical price target raised to $48 from $40 at SunTrust
SunTrust analyst David MacDonald raised his price target on Fresenius Medical to $48 and kept his Buy rating after its Q4 results yesterday, saying the quarter was "marked by solid organic trends, ongoing efficiency gains and strong cash flow." The analyst anticipates the company's 2019 to be a year of investment but sees the incremental spending driving more optimization and positioning Fresenius Medical for "attractive growth opportunities". MacDonald adds that he is positive on the company's pending acquisition of NxStage Medical (NXTM) given the market shift "towards the home".
06/20/19
LEHM
06/20/19
UPGRADE
LEHM
Overweight
Fresenius Medical upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Hassan Al-Wakeel upgraded Fresenius Medical Care to Overweight from Equal Weight and raised his price target for the shares to 81.50 euros from 71 euros. After speaking with CEO Rice Powell and a deep-dive into U.S. dialysis market fundamentals, the analyst believes market concerns around the medium-term sustainability of growth are likely overdone. The analyst has started to see some improvements in the business and believes expectations are now achievable. He now sees a "compelling" risk/reward over the medium term for shares of Fresenius Medical.
GH Guardant Health
$63.82

1.25 (2.00%)

08/07/19
JPMS
08/07/19
NO CHANGE
Target $135
JPMS
Overweight
Guardant Health price target raised to $135 from $90 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Guardant Health to $135 from $90 saying the company last night reported "extremely strong" Q2 results. The quarter saw "robust" clinical testing momentum coupled with upside from biopharma and development services, Peterson tells investors in a research note. He continues to view Guardant as a "best-in-class asset in the attractive liquid biopsy space" and reiterates an Overweight rating on the shares.
08/07/19
ADAM
08/07/19
NO CHANGE
Target $125
ADAM
Buy
Guardant Health price target raised to $125 from $96 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Guardant Health to $125 from $96 following a monster Q2 beat and raise quarter. In addition to its solid revenue growth, gross margins surged. The analyst said he likes the company's long-term strategic thinking, execution, and global vision across cancers in late stage therapy selection, cancer monitoring, and early-stage cancer screening. Massaro reiterated his Buy rating on Guardant Health shares.
09/11/19
ADAM
09/11/19
NO CHANGE
Target $125
ADAM
Buy
Guardant Health should be bought on weakness, says Canaccord
In an earlier research note to investors, Canaccord analyst Mark Massaro reiterated a Buy rating and $125 price on Guardant Health shares, and noted that he met with Guardant Health co-founder and CEO Helmy Eltoukhy and CFO Derek Bertocci. The analyst says the CEO touted innovation, risk-taking, and TAM expansion, and indicated that the analyst's $120B global TAM estimate for Guardant is "not far off." Further, as the company launches new franchises, it sees geometric increases in available market size, and overlapping growth cycles for many years to come, the analyst adds. Despite some recent weakness in shares, Massaro would be a buyer on the dip.
09/12/19
LEER
09/12/19
NO CHANGE
Target $130
LEER
Outperform
Guardant Health recent weakness a buying opportunity, says SVB Leerink
SVB Leerink analyst Puneet Souda views Guardant Health as a best-in-class liquid biopsy opportunity in a massive high growth market, with the company generating a conservative 60% revenue CAGR that is likely to accelerate as the overall LBx market grows. The analyst highlights buying opportunity amid recent weakness, and reiterates an Outperform rating and $130 price target on the shares given the catalyst path ahead over the next year.
IBM IBM
$145.49

2.2 (1.54%)

08/05/19
MSCO
08/05/19
NO CHANGE
Target $170
MSCO
Overweight
IBM guidance with Red Hat in-line with Morgan Stanley expectations
After IBM (IBM) guided calendar year 2019 EPS of "at least" $12.80 when factoring in Red Hat, Morgan Stanley analyst Katy Huberty said this was in-line with her expectation ahead of the event. Following the company's Red Hat presentation, Huberty shifted some of her revenue and EPS forecast into Q4 to reflect the mainframe cycle, but her 2019 estimates for IBM remained otherwise unchanged. Huberty, who thinks Red Hat provides the horizontal platform to bridge the public clouds of AWS (AMZN), Azure (MSFT), GCP (GOOGL), and IBM Cloud, said the "Red Hat acquisition is all about positioning for Chapter 2 of cloud," which will be focused on enterprises' mission critical workloads. Huberty keeps an Overweight rating and $170 price target on IBM shares.
08/06/19
WELS
08/06/19
NO CHANGE
Target $147
WELS
Market Perform
IBM price target raised to $147 from $140 at Wells Fargo
Wells Fargo analyst Ed Caso raised his price target for IBM to $147 from $140 to reflect the recently closed Red Hat acquisition and management's revised 2019 guidance. The analyst reiterates a Market Perform rating on the shares.
08/12/19
JPMS
08/12/19
NO CHANGE
Target $152
JPMS
Neutral
JPMorgan ups IBM target to $152 on favorable view of Red Hat deal
JPMorgan analyst Tien-tsin Huang views IBM's acquisition of Red Hat favorably, saying the asset "should energize" IBM's quest to be the leader in hybrid cloud. The acquisition, while not without risks, could significantly accelerate OpenShift adoption rates, and help Red Hat establish the product as an industry standard in Containerization, Huang tells investors in a research note. He raised his price target for IBM to $152 from $147 but keeps a Neutral rating on the shares. The analyst wants to see proof of integration and execution before getting more constructive on the name.
09/05/19
09/05/19
UPGRADE
Target $12

Outperform
Cloudera upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Patrick Walravens upgraded Cloudera (CLDR) to Outperform from Market Perform with a $12 price target after its Q2 earnings beat and raised FY20 guidance yesterday. The analyst notes that the results were much improved in the latest quarter while also raising his FY20 EPS view to (26c) from (30c). Walravens sees a number of catalysts for Cloudera, including the phased rollout of its Data Platform, new strategic partnerships such as one announced with IBM (IBM) in June, as well as a "new open source licensing and distribution framework that aligns Cloudera's model with industry standards set by Red Hat". The analyst also sees the stock as "quite reasonably valued" at 2.1-times enterprise value to his expected 20201 revenues.
HALO Halozyme
$15.51

0.32 (2.11%)

01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.
07/01/19
CANT
07/01/19
NO CHANGE
Target $27
CANT
Overweight
Halozyme price target raised to $27 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $27 from $24 after including potential future royalty revenues from Enhanze-enhanced drugs developed by partner companies. The analyst continues to view the approval and launch of the Enhanze-based products as "fueling sustainable revenue growth" through 2027, with the Darzalex program as the near-term driver. He sees "notable potential" share upside "almost irrespective" of the outcome of the HALO-301 Phase trial in pancreatic cancer later in 2019. Duncan reiterates an Overweight rating on Halozyme.
09/11/19
CANT
09/11/19
NO CHANGE
CANT
Overweight
Halozyme offers 'low-risk/high-reward' event in Q4, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on shares of Halozyme Therapeutics after a meeting with the company's CEO left him believing that a "clear read" will be seen with the HALO-301 trial in pancreatic cancer later in 2019. However, the analyst continues to see Halozyme share upside "almost irrespective" of the outcome of the Phase 3 trial in Q4. Investors appreciate the high risk in pancreatic cancer, says Duncan, who sees low expectations for Phase 3 success being priced into the current share price. The company's "growing" Enhanze franchise is the major driver of share value going forward post the HALO-301 readout, Duncan contends. He likes the design and rationale of the study, and therefore sees it as a "low-risk/high-reward" binary event.
NSTG NanoString
$21.57

0.35 (1.65%)

10/09/18
UBSW
10/09/18
INITIATION
Target $23
UBSW
Buy
NanoString initiated with a Buy at UBS
UBS analyst Daniel Brennan initiated NanoString with a Buy rating and $23 price target.
10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
03/08/19
JPMS
03/08/19
NO CHANGE
Target $35
JPMS
Overweight
NanoString price target raised to $35 from $20 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for NanoString to $35 saying the company reported "strong" Q4 results. The analyst remains encouraged by signs of continued stabilization in the core portfolio over the last few quarters and "extremely robust" early customer interest in GeoMx. He reiterates an Overweight rating on NanoString shares.

TODAY'S FREE FLY STORIES

03:05
10/14/19
10/14
03:05
10/14/19
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
10/14/19
10/14
03:05
10/14/19
03:05
General news
FX Update: Currencies have opened the week in undramatic fashion »

FX Update: Currencies…

XLNX

Xilinx

$96.18

3.4 (3.66%)

, INTC

Intel

$52.06

0.95 (1.86%)

20:45
10/13/19
10/13
20:45
10/13/19
20:45
Upgrade
Xilinx, Intel rating change at Nomura Instinet »

Xilinx upgraded to Buy…

XLNX

Xilinx

$96.18

3.4 (3.66%)

INTC

Intel

$52.06

0.95 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 20

    Nov

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:49
10/13/19
10/13
19:49
10/13/19
19:49
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

FB

Facebook

$184.20

4.02 (2.23%)

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

T

AT&T

$37.58

0.17 (0.45%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

K

Kellogg

$62.14

-0.27 (-0.43%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

IGMS

IGM Biosciences

$17.53

-0.125 (-0.71%)

19:42
10/13/19
10/13
19:42
10/13/19
19:42
Initiation
IGM Biosciences initiated at Piper Jaffray »

IGM Biosciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37
Hot Stocks
LeMaitre acquires biologic patch business from Admedus »

LeMaitre Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

18:37
10/13/19
10/13
18:37
10/13/19
18:37
Periodicals
SoftBank seeking control of WeWork through financing package, WSJ says »

SoftBank (SFTBY) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

18:34
10/13/19
10/13
18:34
10/13/19
18:34
Hot Stocks
Kodiak Sciences announces safety, efficacy from Phase 1b study of KSI-301 »

Kodiak Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:29
10/13/19
10/13
18:29
10/13/19
18:29
Recommendations
Adverum Biotechnologies analyst commentary at Piper Jaffray »

Adverum '022 looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23
Hot Stocks
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022 »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$56.41

0.55 (0.98%)

18:03
10/13/19
10/13
18:03
10/13/19
18:03
Hot Stocks
ConocoPhillips announces $1.39B agreement to sell interests in Australia-West »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.58

0.17 (0.45%)

, CMCSA

Comcast

$45.53

1.02 (2.29%)

17:18
10/13/19
10/13
17:18
10/13/19
17:18
On The Fly
Box Office Battle: 'Joker' stays at number 1 with another $55M »

"Box Office Battle" is…

T

AT&T

$37.58

0.17 (0.45%)

CMCSA

Comcast

$45.53

1.02 (2.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$58.16

0.83 (1.45%)

LGF.A

Lionsgate

$9.52

0.22 (2.37%)

LGF.B

Lionsgate

$8.97

0.19 (2.16%)

DIS

Disney

$130.08

0.73 (0.56%)

VIAB

Viacom

$23.02

0.505 (2.24%)

VIA

Viacom

$25.45

0.65 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated at Wells Fargo »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.